$VERX

Vertex (VERX) Stock Drops As Profit Rebounds Fail To Ease Growth Doubts

Simply Wall St reports Vertex (VERX) shares fell about 8% to $12.39 after Q2 results. Revenue rose to about $204m and the company swung to profit, with basic EPS of $0.06 and adjusted EBITDA of $51m (25% margin). Cloud and e-invoicing growth guidance and execution concerns left investors divided.

Original reporting
Published Aug 5, 2026, 12:24 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 2:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$VERX
Neutral
medium confidence
Mentioned
$VERX
Relevance
7/10
alphai data visualization · based on simplywall.st
Decision brief

The 30-second read

$VERXNeutralMed
01

Why it matters

Traders can use the reported earnings leverage metrics and the specific growth execution caveats to reassess near-term expectations for cloud growth and ARR acceleration, consistent with the stock’s ~8% drop after the print.

02

Market read

Despite stronger earnings power, the market reaction implies investors are still discounting whether cloud and ARR growth will step up as guided.

03

What to watch

The article cites net revenue retention at 105% and ARR per direct customer up 9.2%, which can support longer-term compounding even if near-term cloud migrations lag plans.

Relevance 7/10Novelty 5/10Timing: post-earnings, same-day reaction

Background

The piece frames Vertex’s Q2 as a mix of improved profitability and recurring-revenue metrics alongside concerns about cloud migration timing and deal execution.

Company-level read

Ticker impact

$VERXNeutralMedium confidence
Context

Vertex shares fell about 8% after Q2 results showed profit rebound and higher adjusted EBITDA, but growth execution doubts persisted.

Expected impact

Near-term volatility likely remains elevated as the market tests whether cloud and ARR growth can re-accelerate beyond timing and execution issues.

Evidence & confidence

The article provides concrete Q2 datapoints (revenue, profit/EPS, adjusted EBITDA and margin) plus specific bear-case execution gaps (slower cloud migrations, installed base expansion below expectations, deal slippage). The stock reaction (down ~8%) indicates the market is not fully convinced by the rebound.

Market effects

Highlights investor sensitivity in tax software and recurring-revenue SaaS to cloud migration pace and net retention quality versus headline profitability.

France and upcoming Germany e-invoicing mandates are cited as ARR drivers, which may influence regional demand expectations for compliance software.

E-invoicing regulatory rollouts in Europe are positioned as a cross-border tailwind, but execution timing remains the key swing factor for valuation.

Counterpoint

The profit rebound and 25% adjusted EBITDA margin expansion suggest operating leverage is real; the cloud slowdown may be timing rather than structural demand weakness.

Key entities

  • Vertex

    Tax software specialist reporting Q2 2026 results with profit rebound, higher adjusted EBITDA margin, and growth execution concerns.

Related articles

$VERXMedAI 8/10

Vertex Q2 Earnings Call Highlights

Vertex (NASDAQ:VERX) said slower cloud conversion is a timing issue, with customers using mixed cloud and on-prem deployments. Management highlighted strong e-invoicing momentum ahead of France and Germany mandates, expecting e-invoicing to affect ARR in Q3 and more in Q4. Q3 guidance: revenue $208M-$211M, adj. EBITDA $55M-$57M; full-year revenue $825M-$830M and adj. EBITDA $206M-$210M.

$VERXMedAI 8/10

Why is Vertex stock sliding today?

Vertex Pharmaceuticals shares fell 12.8% after its post-close Q2 2026 results. The company reported EPS of $0.20 vs $0.19 consensus and revenue of $203.97M vs $202.29M forecast, but Q3 2026 revenue guidance of $208M-$211M (midpoint below ~$211.69M consensus) and free cash flow of $2.7M disappointed. Morgan Stanley downgraded to Equal Weight and cut its price target to $15 from $19.

$VERXMed

Vertex stock tumbles on cloud growth miss, price target cuts

Vertex Inc. (NASDAQ:VERX) shares dropped 13.2% after its Q2 results missed cloud growth expectations and analysts cut price targets. DA Davidson lowered its target to $12 from $15, citing slower cloud conversions and reduced FY26 cloud growth guidance to 18% from 25%. Other analysts also adjusted targets following guidance and deal-cycle comments.

$VERXMedAI 8/10

Vertex Announces Second Quarter 2026 Financial Results

Vertex, Inc. (NASDAQ: VERX) reported Q2 2026 results for the quarter ended June 30, 2026. Total revenue rose 10.5% to $204.0 million, with software subscription revenue up 10.7% to $174.8 million and cloud revenue up 17.9% to $101.7 million. Adjusted EBITDA increased to $51.0 million. Outlook: Q3 revenue $208.0-$211.0 million and adjusted EBITDA $55.0-$57.0 million; FY 2026 revenue $825.0-$830.0 million and adjusted EBITDA $206.0-$210.0 million.

$VERXHigh

Vertex, Inc. (VERX): Results of Operations and Financial Condition

Vertex, Inc. (VERX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 verx-20260803xex99d1.htm EX-99.1 ​ Exhibit 99.1 Vertex Announces Second Quarter 2026 Financial Results KING OF PRUSSIA, PA – August 3, 2026: Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), the Decision-to-Defense™ global indirect tax and compliance company, tod